Aegis reiterates bullish outlook for Auxilium

Peyronie's is "tailor-made for [the company's] urology-focused specialty sales force," Aegis says, regarding the new PD indication for Auxilium Pharmaceuticals' (AUXL -1.3%) Xiaflex.

Analyst Ram Selvaraju also notes that "the significantly higher number of vials of Xiaflex required to treat each Peyronie's disease patient is likely to translate into much greater revenue per patient in this indication vs. Dupuytren's contracture."

Buy rating and $33 target maintained.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs